Website Overview: enspryng-hcp.com
General information
Last Updated: 2024-04-12 (yyyy-mm-dd).
Title: ENSPRYNG satralizumab for NMOSD Treatment Efficacy Safety Prescribing Information
Description: ENSPRYNG satralizumab is an interleukin 6 IL 6 receptor antagonist indicated as monotherapy or with immunosuppressive therapy for the treatment of neuromyelitis optica spectrum disorder NMOSD See full safety for more information
Language: English
Contact information
Telephone
- 18332779338
- 8003321088
- 8888352555
Related Websites
- enspryng.com
- gene.com
- doi.org
- chugai-pharm.co.jp
- aao.org